300119.SZ
瑞普生物
SZSE · Healthcare · C 制造业 · CN
CNY 17.34
−3.24%Year over year
Reported trailing growth
- Revenue
- +6.1%
- EBITDA
- —
- EBIT
- +17.9%
- EPS
- +21.3%
- Free cash flow
- -86.1%
- Operating cash flow
- -67.2%
Forward estimates
Based on analyst estimates
- Revenue
- -72.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +17.7%
- EBITDA
- +9.7%
- EBIT
- +4.8%
- Net income
- +4.9%
- EPS
- +5.6%
- Free cash flow
- +92.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026